InSymbiosis works with a range of biopharma companies (virtual, small, and midsize) from around the world as well as large global pharma companies. The majority of our work is with human therapeutics companies and occasionally companies developing veterinary products.
As of 2019, InSymbiosis has worked on programs supporting over 120 therapeutic products covering small molecules, biologic drugs and more recently, cell-based therapies.
InSymbiosis specializes in the oversight of drug development programs and CRO management. Within this broad area we spend a lot of our time involved in candidate selection programs, non-clinical toxicology programs (supporting IND’s and NDA’s), formulation and CMC programs leading to GMP drug substance and drug product and clinical phase programs (Phases I, II and III).
We are indication agnostic and since our inception in 2005, we have worked on most of the main indications of interest to the pharma industry.
Outsource drug development activities to a network of world-class audited CROs, CMOs and laboratories
Benefit from a unique financial structure that provides directly discounted CRO rates
Investment in assets staged from late discovery to Phase II clinical
Uniquely structured investment deals including both cash for equity and project/asset specific investments
Rapid due diligence process
Access to a network of drug development experts and specialists
Flexibility to hire an expert for 1 hour, 1 day or for an entire program
Experts Network can be combined with CRO Optimizer or investment deals
InSymbiosis is a strategic drug development partner for the biopharma industry. By combining uniquely structured investment deals, cutting-edge cost reduction strategies and a smart outsourcing platform, we help our partners advance their programs towards key clinical and financial milestones. As a result, InSymbiosis has become the drug development partner of choice for many biopharma companies.About us